Clinical Trial - Trial HKUCTR-2807
Access comprehensive clinical trial information for HKUCTR-2807 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dr. Tan-to Cheung and is currently Recruiting. The study focuses on Neoplasm.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
HKUCTR-2807
Phase 2
Recruiting
drug
Trial Details
HKU CLINICAL TRIALS REGISTRY • HKUCTR-2807
Untitled Trial
Neoadjuvant Immunotherapy with anti-PD1 in Borderline Resectable Hepatocellular Carcinoma
Study Focus
Sponsor & Location
Dr. Tan-to Cheung
University Grants Committee
China
Timeline & Enrollment
Phase 2
N/A
Dec 13, 2022
ICD-10 Classifications
Neoplasms
Benign neoplasms
In situ neoplasms
Personal history of other neoplasms
Benign neoplasm: Other specified sites
Data Source
HKU CLINICAL TRIALS REGISTRY
HKUCTR-2807
Non-Device Trial